Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-04

Charlie Wright

Role not yet determined Is this you? Add your title

3 pubs

  • Antiparkinson Agents
  • Parkinson Disease
  • Medication Reconciliation
  • Dopamine D2 Receptor Antagonists
  • Aged
  • Carbidopa
  • Drug Combinations
  • Drug Interactions
  • Hospitalization
  • Humans
  • Levodopa
  • Male
  • Metoclopramide
  • Pharmacists
  • Disease Progression

Biography and Research Information

OverviewAI-generated summary

Charlie Wright's research investigates mechanisms in pediatric osteosarcoma, including the synergistic inhibition of PARP and ATM, which leads to unresolved DNA damage and cohesin-mediated collapse. Wright also studies how dysregulated AKT signaling reprograms osteosarcoma to create a reliance on EP300. Another area of focus is the meta-analysis of neuroblastoma single-cell RNA-seq datasets to identify conserved and divergent gene expression programs across human and preclinical models. Wright has also examined the importance of medication reconciliation in patients with Parkinson's disease.

Metrics

  • Publications: 3

Selected Publications

  • The Importance of Medication Reconciliation in a Patient with Parkinson’s Disease (2025)
    The Senior Care Pharmacist DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

1 Collaborator 3 Institutions 1 Country

Top Collaborators

Similar Researchers

Based on overlapping research topics